Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single Arm, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib Plus Binimetinib Followed by Cemiplimab And Fianlimab in Patients With BRAF Mutated Melanoma and Symptomatic Brain Metastases

NCT06887088 is registered in ClinicalTrials.gov with Grupo Español Multidisciplinar de Melanoma as lead sponsor.

NCT NCT06887088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single Arm, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib Plus Binimetinib Followed by Cemiplimab And Fianlimab in Patients With BRAF Mutated Melanoma and Symptomatic Brain Metastases
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Phase
Phase 2
Overall status
Recruiting
Start date
May 29, 2025
Completion date
January 31, 2028
Enrollment
33 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma and brain metastases, melanoma braf v600e/k mutated